Biotech Values

[dewophile]

i couldn't agree more. to project on hypoglycemia using hgb A1c shows a level of ignorance that any medical student could remedy. monthly monitoring was also a silly design. More frequent monitoring would screen for subclinical hypoglycemia, and in addition there should be careful reporting of clinical signs of hypoglycemia (which should then reflexively require a blood glucose). based on more intense (perhaps even daily) monitoring then one could conclude hypoglycemia not a risk and blood monitoring of little or no value

I too bleieve there is a potential gem here, but the data is incomplete and from what I saw today speaks for a level of competence in management that makes me wary of an investment here